Screener
King Pharmaceuticals KG Benefits, Losses and Expenses, Net
Benefits, Losses and Expenses, Net at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept kg:BenefitsLossesAndExpensesNet.
The source filing: King Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 8:49 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054606
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Change in fair value of earn out liability | — | 2,679 | — | 2,679 |
| Gain on bargain purchase | — | (73,590) | — | (73,590) |
| Foreign exchange and other (gains) losses | (2,278) | 5,102 | (4,498) | 5,102 |
| Total expenses | 14,890 | (64,364) | 32,538 | (63,221) |
| Net (loss) income before income taxes | (8,204) | 69,930 | (15,628) | 69,628 |
| Less: income tax (benefit) expense | (112) | 3 | (106) | 95 |
| Interest in income of equity method investments | 10 | — | 9 | — |
| Net (loss) income | $(8,082) | $69,927 | $(15,513) | $69,533 |
Item 1. Financial Statements
FAQ
- What is King Pharmaceuticals's benefits, losses and expenses, net?
- King Pharmaceuticals (KG) reported benefits, losses and expenses, net of $14.89M in Q2 2026.
- How has King Pharmaceuticals's benefits, losses and expenses, net changed year-over-year?
- King Pharmaceuticals's benefits, losses and expenses, net increased by 123.1% year-over-year, from -$64.36M to $14.89M.
- What does benefits, losses and expenses, net mean?
- Benefits, Losses and Expenses, Net as reported by Kestrel Group Ltd.
Ask your AI about King Pharmaceuticals's benefits, losses and expenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude